Acer Therapeutics  And Relief Therapeutics  Announces Presentation Of Acer-001 Data

0 48

Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics Holding SA, today announced the presentation of data evaluating the bioavailability, bioequivalence, and taste attributes of taste-masked sodium phenylbutyrate (ACER-001) compared to sodium phenylbutyrate (BUPHENYL) powder during poster sessions at the recent Society for Inherited Metabolic Disorders (SIMD) Annual Meeting on April 10-13, 2022 in Orlando, Florida.

“These data further support our belief that, if approved, ACER-001 could offer an alternative to current therapies that may lead to meaningful clinical outcomes in UCDs patients. We are pleased with the outcomes of these studies and look forward to presenting them at future conferences,”

said Adrian Quartel, MD, CMO of Acer. 

“We are highly encouraged by the results of these bioavailability, bioequivalence, and taste attribute studies of ACER-001. We look forward to the U.S. Food and Drug Administration’s decision on the Prescription Drug User Fee Act (PDUFA) target action date on June 5, 2022,” 

said Raghuram (Ram) Selvaraju, Chairman of Relief.

Contact us with your feedback and suggestions.

Leave A Reply

Your email address will not be published.